Who qualifies for Vascepa under Medicare Part D?
Medicare Part D plans cover Vascepa (icosapent ethyl) for patients with cardiovascular disease or diabetes plus additional risk factors who need triglyceride-lowering therapy despite statin use. Key criteria include:
- Established atherosclerotic cardiovascular disease (ASCVD), or
- Type 2 diabetes with one or more risk factors (age ≥50, hypertension, smoking, high LDL).
Prior authorization is typically required to confirm triglycerides ≥150 mg/dL on maximized statin therapy.[1][2]
What about private insurance coverage for Vascepa?
Private insurers like UnitedHealthcare, Aetna, and Cigna often cover Vascepa similarly, requiring:
- Diagnosis of hypertriglyceridemia (≥150 mg/dL).
- Failure or intolerance to statins plus another lipid-lowering agent.
- Documentation of cardiovascular risk.
Step therapy is common, mandating trials of fenofibrate or omega-3 generics first. Copays range from $10–$100 after meeting deductibles.[3][4]
How does prior authorization work for Vascepa?
Payers require physicians to submit:
- Labs showing triglycerides ≥150 mg/dL (fasting).
- Evidence of optimized statin dose for ≥3 months.
- No contraindications like active pancreatitis or allergy.
Approval timelines average 2–7 days; denials often stem from missing statin trial data.[2][5]
What patient assistance options exist if insurance denies Vascepa?
- Manufacturer programs: Amarin's Vascepa Savings Card reduces copays to $9/month for eligible commercially insured patients (income limits apply).
- Patient assistance: NeedyMeds or RxAssist for uninsured/low-income (AGI ≤$50,000 single/$65,000 household).
- Medicaid: Covers with state-specific criteria, often no prior auth needed.
Uninsured cash price is ~$300–$400/month; generics unavailable until patent expiry in 2031.[1][6]
Why do some plans exclude Vascepa or impose high costs?
Post-2020 REDUCE-IT trial, coverage expanded, but some formularies prefer cheaper alternatives like Lovaza. Formulary tiers place Vascepa in Tier 3–4, triggering higher copays. Appeals succeed ~70% with strong CV risk documentation.[4][7]
Sources:
[1]: DrugPatentWatch.com
[2]: CMS Medicare Part D Coverage
[3]: GoodRx Vascepa Coverage
[4]: CoverMyMeds Prior Auth Data
[5]: Amarin Prior Auth Guide
[6]: NeedyMeds Vascepa
[7]: Institute for Clinical and Economic Review (ICER) Report